Hologic

What Hologic does

Hologic is a global medical technology company founded in 1985 and headquartered in Marlborough, Massachusetts, focused on detecting, diagnosing, and treating health conditions affecting women. The company operates three integrated divisions — Women's Health Products, Lab Technologies, and Tests — spanning breast cancer screening and diagnosis (3Dimensions mammography, Genius AI Detection, 3DQuorum, C-View, Brevera biopsy systems), gynecological health (NovaSure, MyoSure, CoolSeal), and molecular diagnostics (Panther and Panther Fusion platforms running Aptima HPV and infectious disease assays, ThinPrep cytology, Breast Cancer Index genomic test). Acquired brands including Endomag (magnetic surgical localization), Biotheranostics (oncology molecular diagnostics), Diagenode (epigenetics tools), Bolder Surgical (vessel sealing), and Gynesonics (minimally invasive fibroid treatment) extend the portfolio across the screening-diagnosis-treatment continuum.

Hologic generates revenue primarily through sales of capital medical devices, diagnostic instruments, and high-margin consumables (assays, biopsy needles, cytology supplies) sold directly to hospitals, imaging centers, OB/GYN practices, and clinical laboratories across 36 countries. The business model combines enterprise hardware sales with recurring assay and consumable usage on installed Panther and ThinPrep platforms, supported by a direct enterprise field sales force, regional distributor network, and the iStore online ordering channel. Q1 2026 revenue was $1.05 billion (up 2.5% YoY), with full-year FY2025 revenue of approximately $4.1 billion and Breast Health alone generating roughly $1.5 billion annually.

In April 2026, Hologic was acquired by Blackstone and TPG in an $18.3 billion take-private transaction, with ADIA and GIC as minority co-investors, delisting from Nasdaq. Joe Almeida, former Chairman and CEO of Baxter International, succeeded longtime CEO Stephen MacMillan. The company holds 4,100+ patents, employs approximately 7,000 people globally, and operates manufacturing facilities in the U.S. (Delaware, California) and Costa Rica (Shingo Prize recipient), plus a Customer Experience Center in Belgium and operations across the UK, Europe, and Asia-Pacific.

Name

Hologic

Legal name

Hologic, Inc.

Website

https://hologic.com

Company type

Private

Founded year

1985

Operating status

Acquired

Headcount range

5,001–10,000 employees

Short description

Hologic is a global medical technology company that develops diagnostics, imaging, and surgical devices focused on women's health — spanning breast and cervical cancer screening, molecular diagnostics, and gynecological procedures. It sells directly to hospitals, OB/GYNs, and laboratories across 36 countries.

Ownership category

akta.pro rank

Product category

Women's Health Medical Technology

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Mammography & Breast Imaging Systems (HLAHABAF)

akta.pro secondary industries

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

Keywords

• Women's health diagnostics
• Mammography systems
• Molecular diagnostics
• Medical imaging devices
• Surgical medical devices

Headquarters

HQ city

Marlborough

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Devices and Diagnostics: Hologic generates revenue primarily from selling medical devices, diagnostic tests, and imaging systems to healthcare providers, hospitals, and laboratories. Revenue streams include mammography equipment, biopsy systems, molecular diagnostic assays, surgical devices, and related consumables.
2. Breast Health Business: Breast health segment generates approximately $1.5 billion in annual sales, including mammography systems, biopsy needles, and related diagnostic equipment.
3. Molecular Diagnostics: Molecular diagnostic testing including HPV tests, STI tests, and other infectious disease assays run on the Panther and Panther Fusion platforms.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Hologic develops and manufactures medical technologies for the detection, diagnosis, and treatment of women's health conditions, with primary products spanning mammography systems (3D tomosynthesis), molecular diagnostic assays (HPV, STI), AI-powered digital cytology systems, minimally invasive gynecological surgical devices, and bone density assessment systems. The company sells these products along with related consumables to hospitals, diagnostic laboratories, breast centers, and OB/GYN practices globally, supplemented by service contracts and clinical education.

Product overview

Hologic offers a comprehensive women's health portfolio organized across three interconnected divisions: Women's Health Products (including Breast Health, Gynecological Health, Sexual Health, Skeletal Health, and Diagnostics), Lab Technologies (Molecular Diagnostics and Cytology platforms), and diagnostic Tests. The Breast Health continuum spans 3Dimensions™ Systems for mammography, Genius Digital Diagnostics System (the first FDA-cleared AI-powered digital cytology system), Genius AI™ Detection Technology for computer-aided mammography analysis, and C-View™ Software for synthetic 2D image generation from 3D tomosynthesis. The Gynecological Health portfolio includes NovaSure® ADVANCED endometrial ablation, MyoSure® tissue removal, and surgical energy systems like CoolSeal®. Lab Technologies feature the Panther® and Panther Fusion® automated molecular testing platforms running Aptima® assays for HPV, infectious diseases, and STIs, along with the ThinPrep® cytology system. The Tests division includes the Breast Cancer Index® genomic test for extended endocrine therapy decision-making. Hologic also integrates acquired brands including Endomag® magnetic localization technology and Diagenode's epigenetics tools, providing an integrated platform from screening and diagnosis through treatment.

Differentiator

Problem solved

Functional benefit

Brands

• Biotheranostics: A Hologic company specializing in oncology molecular diagnostics, including the Breast Cancer Index test for breast cancer treatment decisions
• Endomag
• Diagenode

Products and services

• 3Dimensions Mammography Systems Advanced mammography system providing 3D tomosynthesis imaging for enhanced breast cancer detection, representing Hologic's flagship breast imaging platform. Sold to hospitals, imaging centers, and breast health practices.
• Genius Digital Diagnostics System First and only FDA-cleared AI-powered digital cytology system for cervical cancer screening, using volumetric imaging and AI to identify pre-cancerous lesions and cervical cancer cells from Pap test slides. Sold to diagnostic laboratories.
• Genius AI Detection Technology AI-powered computer-aided detection solution for mammography that identifies areas suspicious of breast cancer, shown to find approximately one additional cancer for every 10 identified by radiologists. Sold to hospitals and breast imaging centers.
• Breast Cancer Index (BCI) Test Molecular gene expression-based test for early-stage HR+ breast cancer patients that predicts likelihood of benefit from extended endocrine therapy beyond five years, with exclusive guideline recognition from NCCN and ASCO. Sold to oncologists and healthcare providers.
• Aptima HPV Assay Molecular diagnostic assay that detects high-risk HPV types causing cervical cancer, approved by FDA in February 2026 for primary cervical cancer screening based on a study of over 650,000 women. Sold to clinical laboratories.
• Panther System Fully automated molecular testing platform that consolidates and runs multiple assays for women's health, infectious disease, and respiratory testing with random-access capabilities. Sold to diagnostic laboratories.
• Panther Fusion System Molecular diagnostics platform for syndromic testing panels covering respiratory pathogens, healthcare-associated infections, and sexually transmitted infections. Sold to diagnostic laboratories.
• ThinPrep Imaging System Automated cytology screening system for cervical cancer detection using the ThinPrep liquid-based Pap test with imaging technology to assist cytologists. Sold to clinical laboratories.
• Endomag Magseed and Sentimag Magnetic breast cancer surgery localization system including Magseed markers for tumor localization and Magtrace lymphatic tracer for sentinel lymph node mapping, providing wire-free, non-radioactive alternative. Sold to hospitals and surgical centers.
• Affirm Prone Breast Biopsy System Prone breast biopsy system for minimally invasive tissue sampling under imaging guidance, part of Hologic's breast biopsy portfolio. Sold to hospitals and breast centers.
• Brevera Breast Biopsy System Advanced breast biopsy system with real-time imaging capability for precise tissue sampling during breast cancer diagnosis. Sold to hospitals and breast imaging centers.
• NovaSure ADVANCED Endometrial ablation system for treatment of heavy menstrual bleeding, using radiofrequency energy to ablate the uterine lining. Sold to OB/GYN specialists and women's health clinics.
• MyoSure Tissue Removal System Minimally invasive surgical system for removal of uterine fibroids and polyps, maintaining uterine integrity. Sold to OB/GYN specialists and hospitals.
• CoolSeal Generator Vessel sealing generator system for laparoscopic surgical procedures, part of the CoolSeal surgical energy portfolio. Sold to hospitals and surgical centers.
• Horizon DXA System Dual-energy X-ray absorptiometry system for bone density assessment and body composition analysis. Sold to hospitals and imaging centers.
• BioZorb 3D Bioabsorbable Marker 3D bioabsorbable marker implanted during breast cancer surgery to mark the tumor site for radiation therapy planning and long-term monitoring. Sold to hospitals and oncology surgical centers.
• SureCare Service Ongoing customer service and support program for Hologic medical device installations, including maintenance, training, and technical support for hospitals and laboratories.

Quantifiable outcome

• AI detection found approximately 90% of confirmed invasive lobular cancers, including 43% of cases initially interpreted as negative during routine screening
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature11 records

Partnerships

Two partnerships are on record, tiered strategic and minor.

• OM1strategicTechnology or Integration · 5 May 2026Real-world evidence company that provided AI platform supporting Hologic's landmark FDA approval study for the Aptima HPV Assay. The study analyzed data from over 650,000 women across multiple U.S. health systems.
• EARN (European Advanced Recycling Network)minorOthersElectronics recycling partner that helps Hologic manage e-waste in compliance with the WEEE Directive, providing certified recycling facilities with full traceability.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Royal Philips: Broader incumbent in medical imaging, including mammography (MicroDose 3D), ultrasound, and patient monitoring. Overlaps with Hologic in women's health imaging as part of a wider hospital equipment portfolio.
• Danaher (Beckman Coulter Diagnostics): Broader incumbent in clinical diagnostics and laboratory instruments with overlapping molecular and immunoassay platforms that compete for the same reference lab and hospital laboratory customers as Hologic's Panther and Panther Fusion systems.
• Becton, Dickinson and Company (BD): Broad incumbent in molecular diagnostics, women's health (including STI and HPV testing via the BD Onclarity HPV assay), and biosciences. Overlaps with Hologic's Panther-based molecular diagnostics franchise as a larger diversified player.

Direct peers

• Roche Diagnostics: Direct competitor in HPV primary screening with the cobas HPV test on the cobas 6800/8800 systems, competing head-to-head with Hologic's Aptima HPV Assay on the Panther platform across U.S. and global cervical screening markets.
• Siemens Healthineers: Direct global competitor in mammography with its Mammomat Revelation and Mammomat B.brilliant 3D tomosynthesis systems. Recently adjudicated against Hologic at the Unified Patent Court, making it the closest functional comparable for women's imaging hardware.
• CooperSurgical: Direct peer in women's health surgical and fertility, with endometrial ablation, hysteroscopic tissue removal, and OB/GYN products that overlap with Hologic's NovaSure, MyoSure, and CoolSeal portfolios in the same physician call point.
• Fujifilm Healthcare: Sells the Amulet Innovality and related 3D mammography systems globally, competing with Hologic in breast tomosynthesis and serving overlapping breast imaging centers and hospital radiology departments.
• GE HealthCare: Competes directly in 3D mammography (Senographe Pristina with tomosynthesis), ultrasound, and adjacent women's health imaging, sharing the same hospital and breast-center customer base as Hologic's 3Dimensions systems.
• Canon Medical Systems: Direct peer in women's imaging with its digital mammography and 3D tomosynthesis product lines, targeting the same radiology and breast center customers as Hologic's 3Dimensions and Genius AI Detection platforms.

Emerging players

• Carl Zeiss Meditec: Comparable in surgical microscopy and intraoperative imaging used in oncology and women's health surgery, with adjacent but partial overlap to Hologic's surgical and biopsy visualization platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/hologic
• YouTubeyoutube.com/user/hologic250
• Facebookfacebook.com/TeknomedMedicalEquipments
• LinkedInlinkedin.com/company/hologic
• Instagraminstagram.com/hologic

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries5 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A21 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hologic